If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-17. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
=== Reactivity === Metallic elements which are more electropositive than hydrogen, particularly the alkali metals and, to a lesser extent, alkaline earth metals, displace hydrogen from water, forming hydroxides and releasing hydrogen. At high temperatures, coke, a form of carbon, reacts with steam to form carbon monoxide and hydrogen.
Pro-gastrin-releasing-peptide, also known as Pro-GRP, is a gastrin-releasing peptide (GRP) precursor, a neurotransmitter that belongs to the bombesin-related neuromedin B family. GRP stimulates the secretion of gastrin in order to increase the acidity of the gastric acid. Pro-GRP is a peptide composed of 125 amino acids, expressed in the nervous system and digestive tract. It is different from progastrin, consisting of 80 amino acids, precursor of gastrin in its intracellular version and oncogene in its extracellular version (hPG80). The presence of GRP in lung cancer samples was identified in 1983. In pathological situations, GRP has mitogenic activity in vitro in many cancers including pancreatic cancer, small cell lung carcinoma, prostate cancer, kidney cancer, breast and colorectal cancer. GRP could operate as an autocrine growth factor. In cancers, GRP induces cell growth and inhibits apoptosis by shutting down the endoplasmic reticulum stress pathway. The mechanisms of the impacted signal pathways have not been established. As early as 1994, research on Pro-GRP as a biomarker for small-cell lung carcinoma began. Because of the very short half-life of GRP (2 minutes), the Pro-GRP is used for measurements and analysis. Since then, Pro-GRP has been used as a tumor marker for patients with small-cell lung carcinoma in limited and extended stages.
=== Versions === The same scale has been validated in Spanish, Brazilian Portuguese, and Polish versions. A version has also been designed and validated for children. More recently, in September 2011, a modified version of the scale was validated using a criterion of self-assessment for ages six–eight years of age. A version of the scale was developed into a chart suitable for use on US television by Gary Kahan of NewYork–Presbyterian Hospital.
Sources: en.wikipedia.org
The aerosol or spallation frangible powder produced by impact and combustion of depleted uranium munitions (or armour) can potentially contaminate wide areas around the impact sites, leading to possible inhalation by human beings. The actual level of acute and chronic toxicity of DU is also controversial. Several studies using cultured cells and laboratory rodents suggest the possibility of leukemogenic, genetic, reproductive, and neurological effects from chronic exposure. A 2005 epidemiology review concluded "In aggregate the human epidemiological evidence is consistent with increased risk of birth defects in offspring of persons exposed to DU." A 2021 study concluded that DU from exploding munitions did not lead to Gulf War illness in American veterans deployed in the Gulf War. A 2011 study found elevated levels of uranium in soil and hair samples from Fallujah, Iraq, but it was from slightly enriched uranium instead of DU.
=== Diabetes === Empagliflozin is indicated in adults with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death; and as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In June 2023, the US Food and Drug Administration (FDA) expanded the indication, as an addition to diet and exercise, to improve blood sugar control in children 10 years and older with type 2 diabetes. Empagliflozin has shown beneficial effects on cardiovascular morbidity and mortality in patients with type 2 diabetes. Additionally, large-scale randomised controlled trials have demonstrated that empagliflozin decreases heart failure hospitalisations and cardiovascular mortality in adults with heart failure, whether they have reduced, mid-range, or preserved left ventricular ejection fraction and regardless of type 2 diabetes status. There is evidence from high quality studies that empagliflozin can also help to slow the rate of kidney function decline. Irrespective of diabetes status, benefit was observed in those with mild, moderate or severe loss of kidney function. People started on empagliflozin may first see a decrease in kidney function before their glomerular filtration rate stabilises. Greatest benefit was demonstrated in those who had severe loss of kidney function, higher risk of kidney function worsening and background of diabetes. Empagliflozin is also available as the fixed-dose combinations empagliflozin/linagliptin, empagliflozin/metformin, and empagliflozin/linagliptin/metformin.
=== Cellular mechanisms === DNA polymerases, used in DNA replication, have a high specificity of 104 to 106-fold in base pairing. They have proofreading abilities to correct incorrect matches, allowing 90-99.9% of mismatches to be excised and repaired. The base mismatches that go unnoticed are repaired by the DNA mismatch repair pathway, also inherent in cells. The DNA mismatch repair pathway uses exonucleases that move along the DNA strand and remove the incorrectly incorporated base in order for DNA polymerase to fill in the correct base.Exonuclease1 is involved in many DNA repair systems and moves 5' to 3' on the DNA strand.
Cassinga must be revenged." It was from this communique that the name of the next major PLAN offensive was derived: Operation Revenge. After some deliberation, Huwala chose Katima Mulilo as his target and dispatched several PLAN reconnaissance teams to obtain data on firing positions and potential artillery observation posts. On 23 August 1978, PLAN bombarded Katima Mulilo with mortars and rocket fire, killing 10 SADF personnel. The next day, General Viljoen, General Geldenhuys and the Administrator-General of South West Africa flew out to Katima Mulilo to inspect the damage. All three narrowly escaped death when their SA.321 Super Frelon helicopter took ground fire from PLAN anti-aircraft positions at Sesheke. The SADF responded by bombarding Sesheke with its own artillery and making a sweep for PLAN insurgents up to a hundred kilometers north of the Cutline. On 6 March 1979, Prime Minister Botha ordered retaliatory strikes on selected targets in Angola and Zambia. The respective code names for the operations were Rekstok and Saffraan. Heliborne South African troops landed in the vicinity of four Angolan settlements: Heque, Mongua, Oncocua, Henhombe, and Muongo, which they canvassed for guerrillas. The SADF remained in Zambia for a significantly longer period, carrying out a series of uneventful combat patrols and ambushes for five weeks. While Operations Rekstok and Saffraan were unsuccessful in terms of tactical results, they did interrupt PLAN's attempts to rebuild its base camps near the border.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.